Navigation Links
IlluminOss(TM) Photodynamic Bone Stabilization System Receives CE Mark
Date:3/23/2009

Allows Commercialization in the European Union

EAST PROVIDENCE, R.I., March 23 /PRNewswire/ -- IlluminOss Medical Inc., a medical device company developing the innovative IlluminOss(TM) Photodynamic Bone Stabilization System for orthopedic surgery, today announced that it had been granted a CE Mark. The approval permits the Company to market this product in the European Union (EU).

IlluminOss Medical is beginning the process of selecting distribution partners in the EU for the IlluminOss Photodynamic Bone Stabilization System.

With traditional methods of treating fractures, often a large incision has to be made; and plates and screws inserted to stabilize the fracture. There may be extensive soft tissue damage; the patient has limited or no mobility initially which may lead to temporary or permanent stiffness; and the patient may experience severe pain.

The IlluminOss Photodynamic Bone Stabilization System requires just a small 4.5mm pathway into the bone to stabilize it. A small diameter balloon catheter and light fiber are inserted into the intramedullary canal of the bone. A photo sensitive, liquid monomer is then infused into the balloon. The monomer expands the balloon to fit the contours of the interior of the bone, aiding in the reduction of the fracture. Then the light source is activated, converting the liquid monomer into a hardened polymer within 90 seconds. The minimal skin incision is then closed.

Unlike other methods of fracture treatment, the IlluminOss Photodynamic Bone Stabilization System is designed to enable the patient to have immediate joint mobility post procedure without the need for immobilization. Due to the minimally invasive approach, soft tissue injury is virtually eliminated. Having immediate mobility minimizes the potential for tendon adhesions and a tenolysis procedure to remove them.

According to Bob Rabiner, Founder and CEO of IlluminOss Medical, "This approval represents a major milestone for IlluminOss and patients in the EU. We believe that our minimally invasive technology will fundamentally improve the treatment of hundreds of thousands of bone fractures by driving much earlier restoration of functionality, improving the durability of orthopedic repairs, decreasing pain and reducing scarring."

About IlluminOss Medical Inc.

IlluminOss Medical is a privately held, early-stage medical device company dedicated to the development of minimally invasive orthopedic systems for the stabilization and treatment of bone fractures. The IlluminOss Photodynamic Bone Stabilization System utilizes a photodynamic (light-curable) polymer system intended to eliminate the need for traditional, inconvenient and painful methods of bone fixation with external pins, plates and screws. The Company is currently developing the IlluminOss Photodynamic Bone Stabilization System for small bones such as fractures of the hands, wrists, clavicle and arms. It is anticipated that the IlluminOss Photodynamic Bone Stabilization System will also have applications in the spine and long bones.

Founded in 2007, IlluminOss is headquartered in East Providence, RI. For more information about IlluminOss Medical, please visit www.illuminoss.com.

    Company Contact:                             Media Contact:
    Bob Rabiner                                  Stephen Sandler
    (401) 714-0008 ext. 207                      (508) 358-7206 ext. 202
    rrabiner@illuminoss.com                      ssandler@vmark.net


'/>"/>
SOURCE IlluminOss Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. IlluminOss Announces First Human Case Utilizing Its Innovative Photodynamic Bone Stabilization System Technology
2. Combined stenting and photodynamic therapy improves survival in late stage liver cancer patients
3. NJHA: Hospital Needs Exceed Stabilization Fund Resources
4. Scientx Announces FDA 510(K) Clearance for Isobar DUO(TM) Dynamic Stabilization System
5. Zimmer Spine Introduces New Rigid to Dynamic Stabilization Transition System
6. Healthcare Tech and the World: Advancing Autonomy in the UK Healthcare System
7. U.S. FDA Approves New THERAKOS(TM) CELLEX(TM) Photopheresis System
8. Orcas Family Health Center Installs First Ultrasound System on Island
9. Thus I Became Stress Free, Oh Really?: Systematically Manage and Optimize Stress to Improve Productivity, Happiness
10. MTM Upgrades its Phone System to Ensure Leading edge Technology and Software Feature sets for Existing and Future Clients
11. University HealthSystem Consortium Selects KONE to Provide Elevator Maintenance Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology: